Andy brings a background spanning institutional capital and hands-on company-building to Engitix. He joins from Purespring Therapeutics, a University of Bristol spinout developing a first-in-class renal gene therapy, where as employee number four he established and built the corporate foundations — positioning the company for a Series B financing.

Earlier in his career, Andy spent several years at Imperial College university sitting at the intersection of finance and innovation: attending the investment committee as the endowment grew 7x, supporting the financing and development of the estate, and serving on the Board overseeing 185,000 sq ft of incubator and scale-up space at White City. It was here he developed a close understanding of how science-led companies are built, funded and scaled.

Andy holds a degree in Biochemical Engineering from University College London and is a Fellow of the Institute of Chartered Accountants.